The global oncology biomarker space is experiencing a wave of transformational growth, mainly driven by demand for early detection and diagnosis, increasingly comprehensive biomarker panels, rising adoption of biomarker-linked therapies, and surging adoption of next-generation sequencing (NGS), predictive biomarkers, and liquid biopsy. Growth is supported by declining costs of biomarker tests, developing technology, and robust clinical validation.

The industry is witnessing an increase in clinical activity and biopharma-led innovation, and a rapidly evolving, biomarker-driven therapeutic paradigm. In 2024, the industry observed sustained R&D momentum. In 2022, clinical trial activity hit a high, with 22% more than in 2018. Treatment access has also increased, especially in pharma emerging segments, supporting a 5% yearly growth in the number of treated patients.

The global oncology drugs space is expected to reach revenue of $217.13 billion by 2025 and $294.01 billion by 2030 at a CAGR of 6.25% (2025–30), driven by high-cost targeted therapies, longer treatment durations, and biomarker-linked therapies that allow for further patient segmentation. The majority of oncology industry sales are for the leading types of cancer (breast, lung, colorectal, prostate, and cervical).

By 2030, the oncology biomarkers diagnostics value chain will have changed due to the adoption of multi-analyte and multi-modal testing platforms, encouraged by evolving reimbursement regimes in the European Union and Asia-Pacific. In breast and colorectal cancers, predictive biomarkers, which are used to choose targeted therapies, are gaining traction. Companion diagnostics are becoming the standard of care. Prognostic biomarkers, which measure the course and recurrence of diseases, are seeing growing adoption, particularly for use in guiding adjuvant therapy decisions.

• Which growth avenues are emerging due to the use of liquid biopsy-based diagnostics in prognostic and predictive applications in clinical settings, and the adoption of biomarker-based diagnostics owing to regulatory support?
• Why are multiplexed, NGS-based assays backed by digital pathology and bioinformatics replacing single-marker platforms?
• How will emerging technologies and biomarkers within the oncology biomarker space, along with multi-parametric, pan-cancer diagnostics, drive long-term growth?
• What factors will propel growth across different segments based on technology types, cancer types, application types, and end-user segment offerings?